Table 2 Epigenetic regulation of tumor cell ferroptosis
Gene | Title | Epigenetic modulation | Cancer |
|---|---|---|---|
GPX4/ACSL4 | Polyunsaturated fatty acid biosynthesis pathway determines ferroptosis sensitivity in gastric cancer | DNA methylation | Gastric cancer |
16 CpG sites | Ferroptosis-associated DNA methylation signature predicts overall survival in patients with head and neck squamous cell carcinoma | DNA methylation | Head and neck squamous cell carcinoma |
TFRC/ACSL4 | ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2/HO−1 axis | DNA methylation | Glioma |
ZEB1/DUOX1 | Identification and Validation of Ferroptosis-Related DNA Methylation Signature for Predicting the Prognosis and Guiding the Treatment in Cutaneous Melanoma | DNA methylation | Cutaneous Melanoma |
SLC7A11/H3K9/H2A | Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy | DNA methylation/ Histone modification | Multiple human cancers |
NR4A2/GPX4/H2A/ H3/H4 histone | Ferroptosis Induction in Multiple Myeloma Cells Triggers DNA Methylation and Histone Modification Changes Associated with Cellular Senescence | DNA methylation/ Histone modification | Multiple myeloma |
OTUB1/SLC7A11 | The ubiquitin hydrolase OTUB1 promotes glioma cell stemness via suppressing ferroptosis through stabilizing SLC7A11 protein | Histone modification | Glioma |
OTUB1/SLC7A11 | The Deubiquitylase OTUB1 Mediates Ferroptosis via Stabilization of SLC7A11 | Histone modification | Bladder cancer |
H3K9me3/H3K27me3/ SLC7A11 | Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells | Histone modification | Breast cancer |
H2B/SLC7A11 | Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53 | Histone modification | Hepatocellular carcinoma |
miR−200 family | Epigenetic reprogramming of epithelial-mesenchymal transition promotes ferroptosis of head and neck cancer | Non-coding RNAs | Head and neck cancer |
miR−522/ALOX15 | CAF secreted miR−522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer | Non-coding RNAs | Gastric cancer |
lncRNA H19/miR−19b−3p/FTH1 | Curcumenol triggered ferroptosis in lung cancer cells via lncRNA H19/miR−19b−3p/FTH1 axis | Non-coding RNAs | Lung cancer |
miR−545−3p/SLC7A11 | Circular RNA Circ_0067934 Attenuates Ferroptosis of Thyroid Cancer Cells by miR−545−3p/SLC7A11 Signaling | Non-coding RNAs | Thyroid Cancer |
miR−27a−3p | CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR−27a−3p | Non-coding RNAs | Esophageal cancer |
LINC00336 | Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA | Non-coding RNAs | Lung cancer |
ACSL4 | Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs | Non-coding RNAs | Pancreatic cancer |
lncRNA DACT3-AS1 | Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer | Non-coding RNAs | Gastric cancer |
miR−23a−3p/ACSL4 | Epigenetic regulation of ferroptosis via ETS1/miR−23a−3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma | Non-coding RNAs | Hepatocellular carcinoma |
miR−137/SLC1A5 | miR−137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma | Non-coding RNAs | Melanoma |
YTHDF1/PD-L1 | N6-methyladenosine regulator YTHDF1 represses the CD8 + T cell-mediated antitumor immunity and ferroptosis in prostate cancer via m6A/PD-L1 manner | m6A modification | miR−3173−5p/ACSL4 |
FTO/SLC7A11 | FTO Prevents Thyroid Cancer Progression by SLC7A11 m6A Methylation in a Ferroptosis-Dependent Manner | m6A modification | Thyroid Cancer |
METTL3/SLC7A11 | RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m6A-dependent manner | m6A modification | Glioblastoma |
METTL3/SLC7A11 | The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma | m6A modification | Hepatoblastoma |
METTL3/SLC7A11 | METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m6A modification | m6A modification | Lung adenocarcinoma |
YTHDC2/SLC7A11/ SLC3A2 | Targeting SLC3A2 subunit of system XC- is essential for m6A reader YTHDC2 to be an endogenous ferroptosis inducer in lung adenocarcinoma | m6A modification | Lung adenocarcinoma |
METTL3/FSP1 | Exosomal miR−4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis | m6A modification | Non-small cell lung carcinoma |
METTL14/SLC7A11/ FPN1 | N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer | m6A modification | Breast cancer |
YTHDF2/CBS/ACSL4 | Hypoxia inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent modulation of CBS in gastric cancer | m6A modification | Gastric cancer |
ALKBH5/GPX4/ SLC7A11 | ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2/HO−1 axis | m6A modification | Thyroid cancer |